Promoted Content
Promoted Content

Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Ispen

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              INDIA India

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Ipsen Gets FDA Fast Track Designation for Irinotecan Liposome Injection as a Second Line Monotherapy Treatment for small Cell Lung Cancer

              Contact the Supplier

              Lead Product(s): Irinotecan

              Therapeutic Area: Oncology Product Name: Onivyde

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 30, 2020

              Details:

              U.S FDA has granted the company Fast Track designation for irinotecan liposome injection (Onivyde) in study patients with small cell lung cancer (SCLC) who progressed following a first-line platinum-based regimen, reflecting the unmet medical need.

              Natco Pharma Limited

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              INDIA India

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              USP Workshop 2021

              Participation Not Confirmed

              Update your events

              Natco Pharma's Canadian Unit Signs Pact with Celgene for Cancer Treatment Drug

              Contact the Supplier

              Lead Product(s): Lenalidomide

              Therapeutic Area: Oncology Product Name: Revlimid

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bristol-Myers Squibb

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement July 10, 2020

              Details:

              Natco Pharma has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada.

              PharmaCompass__DigitalAd